We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Endo Gains Control of Two Collagenase Therapies in BioSpecifics Purchase
Endo Gains Control of Two Collagenase Therapies in BioSpecifics Purchase
Endo International announced that it will purchase the biopharmaceutical company BioSpecifics Technologies for approximately $540 million giving the company complete control over two promising collagenase-based therapies.